OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
OncoGenex Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 21, 2022
OncoGenex Pharmaceuticals reported fiscal year 2021 executive compensation information on April 21, 2022.
In 2021, three executives at OncoGenex Pharmaceuticals received on average a compensation package of $1.3M, a 49% increase compared to previous year.
Average pay of disclosed executives at OncoGenex Pharmaceuticals
John Bencich, Chief Executive Officer, received $1.6M in total, which increased by 82% compared to 2020. 40% of Bencich's compensation, or $648K, was in option awards. Bencich also received $302K in non-equity incentive plan, $465K in salary, as well as $196K in stock awards.
Richard Stewart, Chairman, received a compensation package of $1.3M, which increased by 29% compared to previous year. 41% of the compensation package, or $540K, was in option awards.
Cindy Jacobs, Chief Medical Officer, earned $1.1M in 2021, a 37% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 21, 2022.